Slow Off-Rate Modified Aptamer Arrays for Biomarker Discovery and Diagnostic Applications
DNA microarrays are currently playing a central role in biomarker discovery and in the development of diagnostics for personalized medicine. Our vision is a technology that enables proteomics in the same revolutionary way that DNA microarrays enabled nucleic acid-based omics, allowing simple, reliable, sensitive, accurate, quantitative, and highly multiplexed measurements for the discovery of protein biomarkers and the development of new diagnostics to transform personalized medicine. We recently reached an important milestone, making unbiased protein biomarker discovery routine and fast. Microarrays played a prominent role in our experiments and will be central to the ongoing evolution of our platform. Our technology is powered by a new class of single-stranded DNA-based protein affinity binding reagents we call SOMAmers—slow off-rate modified aptamers. SOMAmers have a dual nature that is essential in our work: under normal conditions (e.g., physiologic in serum), SOMAmers fold into specific shapes that bind target proteins with high affinity (sub-nM K d), but when SOMAmers are denatured, they can be detected and quantified by hybridizing to a standard DNA microarray.
KeywordsChronic Kidney Disease Chronic Kidney Disease Progression Discovery Platform Proteomics Platform Affinity Reagent
We thank all our colleagues who have contributed to developing SomaLogic’s unbiased, high-scale proteomics technology and in particular those who developed SOMAmers and the SOMAscan proteomics assay for biomarker discovery. We especially thank Nebojsa Janjic, Nick Saccomano, and Steve Williams and their research groups for their dedicated efforts in developing this technology.
- Boyle P, Levin B (2008) World cancer report. International Agency for Research on Cancer, LyonGoogle Scholar
- Gold L, Janjic N, Jarvis T et al (2010b) Aptamers and the RNA world, past and present. In: Atkins JF, Gesteland RF, Cech T (eds) RNA worlds, 3rd edn. Cold Spring Harbor, NY, pp 343–341Google Scholar
- Pepe MS, Etzioni R, Feng Z et al (2001) Phases of biomarker development for early detection of cancer OF. Cancer 93:1054–1061Google Scholar
- Zichi D, Koga T, Greef C et al (2002) Photoaptamer technology: development of multiplexed microarray protein assays. Clin Chem 48:1865–1867Google Scholar